D. E. Shaw & Co., Inc. Affimed N.V. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $18,302 - $34,678	-32,110 Reduced 11.18%	255,159 $153,000
Q1 2023 May 15, 2023	BUY	$0.66 - $1.29 $145,619 - $284,620	220,636 Added 331.12%	287,269 $215,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $73,296 - $163,250	66,633 New	66,633 $82,000
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $323,274 - $425,614	-60,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $30,763 - $41,703	5,553 Added 10.16%	60,200 $372,000
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $4.66 Million - $6.83 Million	-599,267 Reduced 91.64%	54,647 $464,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $941,885 - $1.56 Million	183,962 Added 39.14%	653,914 $5.17 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $363,965 - $809,708	115,179 Added 32.47%	469,952 $2.74 Million
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $141,043 - $204,643	43,265 Added 13.89%	354,773 $1.2 Million
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $282,284 - $827,200	178,661 Added 134.49%	311,508 $1.44 Million
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $14,623 - $30,668	-10,155 Reduced 7.1%	132,847 $210,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $17,826 - $24,323	7,923 Added 5.87%	143,002 $392,000
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $261,043 - $356,856	97,769 Added 262.05%	135,079 $397,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $63,858 - $103,401	24,561 Added 192.65%	37,310 $107,000
Q1 2019 May 15, 2019	BUY	$3.05 - $4.34 $3,226 - $4,591	1,058 Added 9.05%	12,749 $54,000
Q4 2018 Feb 14, 2019	BUY	$2.82 - $4.67 $32,968 - $54,596	11,691 New	11,691 $36,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account